{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166265221",
    "name" : "Annotation of DPWG Guideline for olanzapine and CYP1A2",
    "alternateDrugAvailable" : false,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1451697982,
        "date" : "2022-02-28T00:00:00-08:00",
        "type" : "Create",
        "version" : 1
      },
      {
        "id" : 1451704267,
        "date" : "2022-03-03T16:33:37.260-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451732906,
        "date" : "2022-03-28T09:57:50.908-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451884460,
        "date" : "2022-09-16T10:59:08.716-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452063360,
        "date" : "2023-04-07T15:18:15.152-07:00",
        "description" : "added DPWG guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146476,
        "date" : "2023-07-03T13:39:55.536-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452411640,
        "date" : "2024-03-18T11:34:06.207-07:00",
        "description" : "Updated links for risk analysis pdf.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452424661,
        "date" : "2024-03-29T11:50:53.012-07:00",
        "description" : "Removed message about gene information document availability.",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15142974,"title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923774","crossReferences":[{"id":1452412000,"resource":"PubMed Central","resourceId":"PMC10923774","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923774"},{"id":1452056756,"resource":"PubMed","resourceId":"37002327","_url":"https://www.ncbi.nlm.nih.gov/pubmed/37002327"},{"id":1452056757,"resource":"DOI","resourceId":"10.1038/s41431-023-01347-3","_url":"http://dx.doi.org/10.1038%2Fs41431-023-01347-3"}],"objCls":"Literature","pubDate":"2024-03-01T00:00:00-08:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA450688",
        "name" : "olanzapine",
        "version" : 7
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA27093",
        "symbol" : "CYP1A2",
        "name" : "cytochrome P450 family 1 subfamily A member 2",
        "version" : 6459
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1451697980,
      "html" : "<p>There are currently no recommendations for olanzapine dosing based on CYP1A2 genotypes.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451697981,
      "html" : "<h3 id=\"dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-between-cyp2d6-cyp3a4-and-cyp1a2-and-antipsychotics-european-journal-of-human-genetics-2023\">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.  European journal of human genetics (2023)</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines for olanzapine  and CYP1A2 as per the May 2021 guidelines and further details on the assessed literature [Article:<a href=\"/pmid/37002327\">37002327</a>]. Supplementary Table 12B: &quot;Suggested clinical decision support texts for health care professionals for CYP1A2-olanzapine&quot; states for CYP1A2 genotype or phenotype - olanzapine  pairs &quot;This is NOT a gene-drug interaction.&quot;.</p>\n<h3 id=\"may-2021-guideline\">May 2021 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for olanzapine based on CYP1A2 genotypes. They conclude that this is NOT a gene-drug interaction, (see <a download=\"DPWG_May_2021.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_May_2021.pdf\">Dutch guidelines May 2021 update</a>).</p>\n<p><a download=\"DPWG_CYP1A2_olanzapine_4646-to-4651.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_CYP1A2_olanzapine_4646-to-4651.pdf\">Read for more information about this recommendation</a>, <a download=\"CYP1A2.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/CYP1A2.pdf\">Read about gene information from DPWG</a></p>\n",
      "version" : 4
    },
    "version" : 8
  }
}